Last updated: February 20, 2026
What is the current market status for NDC 72603-0590?
NDC 72603-0590 corresponds to Blincyto (blinatumomab), a bispecific T-cell engager used to treat certain types of acute lymphoblastic leukemia (ALL). Since its FDA approval in 2014, Blincyto has maintained a niche market aligned with hematology-oncology treatments. The drug's treatment indications are limited to relapsed or refractory B-cell precursor ALL in adults and pediatric patients.
Market conditions hinge on the following factors:
- Market size: The annual incidence of relapsed/refractory ALL in the U.S. is approximately 600-800 cases.
- Treatment landscape: Blincyto competes with chemotherapy, CAR T-cell therapies such as Kymriah (tisagenlecleucel), and other immunotherapies.
- Pricing: Current wholesale acquisition cost (WAC) stands around $178,000 per treatment course, with net prices influenced by rebates, discounts, and payor negotiations.
How does the competitive environment influence current prices?
Blincyto has maintained a relatively high price point compared to traditional chemotherapies based on its targeted mechanism. However, competition from CAR T-cell therapies, which sometimes offer durable remissions, has pressured pricing and market penetration.
Key competitors include:
- Kymriah (tisagenlecleucel): Offered around $475,000 for pediatric indications but has seen pricing discounts for adult relapsed ALL.
- Juno’s Breyanzi (lisocabtagene maraleucel): Priced approximately $410,000 in its initial launch.
- Chemotherapy regimens: Cost less but with lower efficacy and higher toxicity.
Reimbursement policies and evolving guidelines are influencing market share shifts among these therapies.
What are the pricing trends and projections?
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) |
Comments |
| 2014 |
$175,000 |
Initial launch price |
| 2018 |
$180,000 |
Slight increase; market stability |
| 2020 |
$178,000 |
Price stabilization, competitive pressure |
Price Projections (Next 2-5 Years)
| Year |
Estimated WAC (USD) |
Influencing Factors |
| 2023 |
$170,000 |
Reimbursement negotiations, market saturation |
| 2024 |
$165,000 |
Entry of generic alternatives, if approved |
| 2025 |
$160,000 |
Increased competition, potential biosimilar emergence |
Price reductions may accelerate if biosimilar versions of blinatumomab enter the market by 2025-2026, potentially reducing prices by 15-25%.
Impact of Biosimilars
No biosimilar versions of blinatumomab currently exist in the U.S. However, biosimilar development is underway in Europe, with potential approval in the U.S. within 3-4 years. Biosimilar entry could trigger a 30-40% price decrease and shift market share away from the originator.
Summary of key market drivers
- The small patient population limits total revenue, which constrains high pricing elasticity.
- The competitive landscape, especially CAR T-cell therapies, limits pricing power.
- Technological advances and pipeline developments could impact demand and pricing.
- Reimbursement policies influence access and profitability.
Conclusions
Blincyto remains a niche but essential therapy for relapsed/refractory ALL, with current pricing hovering around $170,000. The introduction of biosimilars could reduce prices significantly by 2025. Strategic market positioning and ongoing clinical data will shape its future revenue potential.
Key Takeaways
- The market size for Blincyto is limited by the rare nature of its indication.
- Current prices are around $170,000 per treatment course, with slight downward pressure projected.
- Competition from CAR T-cell therapies and biosimilars is poised to influence future pricing.
- Market dynamics indicate potential price drops of 15-40% within 3-5 years if biosimilars enter U.S. markets.
- Market share will depend heavily on reimbursement, clinical efficacy, and safety profiles.
FAQs
1. How does Blincyto's price compare to CAR T-cell therapies?
Blincyto’s price (~$170,000) is substantially lower than CAR T therapies (~$410,000 to $475,000). However, CAR T-cell therapies often provide longer-lasting remissions, affecting overall cost-effectiveness.
2. What factors could accelerate biosimilar entry?
Regulatory approval delays, intellectual property disputes, and market demand influence biosimilar competition. Biosimilars are expected to become available within 3-4 years, with potential price reductions of 30-40%.
3. How has COVID-19 impacted Blincyto's market?
The pandemic led to decreased hospital visits and delays in care, slightly reducing treatment volume. Long-term impacts are uncertain but may include increased adoption of outpatient therapies.
4. What is the outlook for reimbursement and insurance coverage?
Coverage remains favorable, owing to the drug's clinical benefits. Reimbursement policies will adapt to biosimilar competition and evolving treatment guidelines.
5. Which regions are most significant for Blincyto sales?
The U.S. accounts for the majority of sales, with Europe and Japan representing smaller but growing markets driven by regulatory approval and clinical adoption.
References
- Food and Drug Administration. (2014). FDA approves first immunotherapy for adults and children with certain types of leukemia.
- IQVIA. (2022). National Prescription Audit.
- SSR Health. (2022). Estimated net price analysis for biologics.
- EvaluatePharma. (2022). World Preview 2027: Biotech and pharma market forecasts.
- FDA. (2022). Biosimilar and Interchangeable Products.
